Visioneering Technologies, Inc. Enters European Market
October 08 2018 - 6:37PM
Business Wire
Names Medilens Nordic AB Its First Authorized
European Distributor for the NaturalVue® Brand Contact Lenses
Visioneering Technologies, Inc. (ASX: VTI), an innovative
US-based medical device company dedicated to developing advanced
products that improve vision, today announced that Medilens Nordic
AB has been named an Authorized Distributor for the innovative
NaturalVue® (etafilcon A) Brand 1 Day Contact Lenses. One of the
leading ophthalmology-focused medical device companies in the
Nordic region and headquartered in Helsingborg, Sweden, Medilens
Nordic AB is Visioneering’s first European distributor. This
partnership marks Visioneering’s entry into the European
market.
Medilens Nordic AB operates in Sweden, Norway, Denmark, Finland
and Iceland, providing a large suite of products to Eye Care
Professionals (ECPs). Important to VTI, Medilens Nordic employs a
highly trained sales force that includes opticians, pharmacists,
and other technically trained specialists that call on over 1400
ECPs.
“Medilens Nordic strives to maintain leadership in our field by
providing our customers with the very best products, expertise,
services and value,” said Kent Maack, Managing Director. “We
believe that Visioneering’s revolutionary NaturalVue® 1 Day Contact
Lenses are taking us to the leading edge of vision technology.
We’re thrilled to be the first distributor to introduce these new
contact lenses in not only the Nordic region, but also the first in
all of Europe.”
“Medilens Nordic is an ideal partner for Visioneering not only
for their stellar reputation, but also because they work closely
with eye care professionals in both public and private healthcare,”
said Tony Sommer, Senior Vice President of Sales and Marketing for
VTI. “Maintaining close relationships with eye care professionals
is our sweet spot. It’s core to our marketing philosophy, just as
it is to Medilens Nordic’s. We’re looking forward to a long and
productive relationship with them.”
About Visioneering Technologies, Inc.
Visioneering Technologies, Inc. (VTI) is a US-based medical
device company primarily engaged in the design, manufacture, sale
and distribution of a revolutionary new contact lens: the
NaturalVue® Multifocal (MF) contact lens. The NaturalVue MF contact
lens employs VTI’s Neurofocus Optics® technology, which was
developed, refined and tested over many years. The characteristics
of the NaturalVue MF contact lens allow it to be used in two of the
largest eye-care markets globally: adults with presbyopia
(age-related difficulty in seeing close objects) and children with
myopia (near-sightedness, or difficulty seeing distant
objects).
NaturalVue lenses were cleared by the FDA in late 2014 and
received the CE Mark, as well as TGA and MedSafe approval in early
2018. VTI recently commenced its US market expansion for NaturalVue
MF contact lenses in 2017, and has broadened its reach into
international markets in 2018. VTI also sells and plans additional
contact lens products.
Foreign Ownership Restriction:
VTI’s CHESS Depositary Interests (CDIs) are issued in reliance
on the exemption from registration contained in Regulation S of the
US Securities Act of 1933 (Securities Act) for offers or sales
which are made outside the US. Accordingly, the CDIs have not been,
and will not be, registered under the Securities Act or the laws of
any state or other jurisdiction in the US. The holders of VTI’s
CDIs are unable to sell the CDIs into the US or to a US person
unless the re-sale of the CDIs is registered under the Securities
Act or an exemption is available. Hedging transactions with regard
to the CDIs may only be conducted in accordance with the Securities
Act.
Forward-Looking Statements:
This announcement contains or may contain forward-looking
statements that are based on management’s beliefs, assumptions and
expectations and on information currently available to
management.
All statements that address operating performance, events or
developments that we expect or anticipate will occur in the future
are forward-looking statements. These include, without limitation,
U.S. commercial market acceptance and U.S. sales of our product as
well as, our expectations with respect to our ability to develop
and commercialize new products.
Management believes that these forward-looking statements are
reasonable when made. You should not place undue reliance on
forward-looking statements because they speak only as of the date
when made. VTI does not assume any obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise. VTI may not actually
achieve the plans, projections or expectations disclosed in
forward-looking statements. Actual results, developments or events
could differ materially from those disclosed in the forward-looking
statements.
MKT-VTI-PR63
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181008005816/en/
CompanyVisioneering Technologies, Inc.Stephen
SnowdyCEOssnowdy@vtivision.comorInvestor and media
relationsWE BuchanLauren Nowak, +61 (3) 9866
4722lnowak@buchanwe.com.au
Visioneering Technologies (ASX:VTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Visioneering Technologies (ASX:VTI)
Historical Stock Chart
From Apr 2023 to Apr 2024